Clopidogrel resistance "Live" - The risk of stent thrombosis should be evaluated before procedures

Thrombosis Journal

Volumn 7, Issue , 2009, Pages

  Motovska, Zuzana ^a   Widimsky, Petr ^a   Marinov, Iuri ^b   Petr, Robert ^a   Hajkova, Jaroslava ^c   Kvasnicka, Jan ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; ORAL ANTIDIABETIC AGENT; RAMIPRIL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AGED; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CASE REPORT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN PHOSPHORYLATION; SMOKING; ST SEGMENT ELEVATION; STENT THROMBOSIS; SWELLING; THORAX PAIN; THROMBOCYTE ACTIVATION; VERTIGO;

EID: 67949092823     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-7-6     Document Type: Article

References (21)

1. Silber S Albertsson P Aviles FF Camici PG Colombo A Hamm C Jorgensen E Marco J Nordrehaug JE Ruzyllo W Urban P Stone GW Wijns W Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 2005, 26(8):804-847 10.1093/eurheartj/ehi138 15769784
2. Smith SC Jr Feldman TE Hirshfeld JW Jr Jacobs AK Kern MJ King SB 3rd Morrison DA O'Neil WW Schaff HV Whitlow PL Williams DO Antman EM Adams CD Anderson JL Faxon DP Fuster V Halperin JL Hiratzka LF Hunt SA Nishimura R Ornato JP Page RL Riegel B American College of Cardiology/ American Heart Association Task Force on Practice Guidelines; ACC/AHA/ SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 2006, 113(7):e166-286 10.1161/CIRCULATIONAHA.106.173220 16490830
3. Wenaweser P Rey C Eberli F Togni M Tuller D Locher S Remondino A Seiler C Hess OM Meier B Windecker S Stent thrombosis following bare-metal stent implantation success of emergency percutaneous coronary intervention and predictors of adverse outcome Eur Heart J 2005, 26(12):1180-1187 10.1093/eurheartj/ehi135 15728650
4. Doyle B Rihal CS O'Sullivan CJ Lennon RJ Wiste HJ Bell M Bresnahan J Holmes DR Jr Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents Circulation 2007, 116(21):2391-2398 10.1161/CIRCULATIONAHA.107.707331 17984377
5. Barragan P Bouvier JL Roquebert PO Macaluso G Commeau P Comet B Lafont A Camoin L Walter U Eigenthaler M Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 2003, 59(3):295-302 10.1002/ccd.10497 12822144
6. Gurbel PA Bliden KP Samara W Yoho JA Hayes K Fissha MZ Tantry US Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study J Am Coll Cardiol 2005, 46(10):1827-1832 10.1016/j.jacc.2005.07.056 16286166
7. Wenaweser P Dörffler-Melly J Imboden K Windecker S Togni M Meier B Haeberli A Hess OM Stent thrombosis is associated with an impaired response to antiplatelet therapy J Am Coll Cardiol 2005, 45(11):1748-1752 10.1016/j.jacc.2005.01.058 15936599
8. Nguyen TA Diodati JG Pharand C Resistance to clopidogrel: A review of the evidence J Am Coll Cardiol 2005, 45(8):1157-64 10.1016/ j.jacc.2005.01.034 15837243
9. Motovska Z Widimsky P Kvasnicka J Petr R Bilkova D Hajkova J Marinov J Simek S Kala P on behalf of the PRAGUE 8 study investigators High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism- a genetic substudy of PRAGUE-8 trial Blood Coagul Fibrinolysis 2009
10. Widimsky P Motovska Z Simek S Kala P Pudil R Holm F Petr R Bilkova D Skalicka H Kuchynka P Poloczek M Miklik M Maly M Aschermann M on behalf of the PRAGUE-8 trial Investigators Clopidogrel pretreatment in stable angina: For all patients > 6 hours before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicenter trial PRAGUE-8 Eur Heart J 2008, 29(12):1495-1503 2429977 18441320 10.1093/eurheartj/ehn169
11. Aleil B Ravanat C Cazenave JP Rochoux G Heitz A Gachet C Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J Thromb Haemost 2005, 3(1):85-92 10.1111/j.1538-7836.2004.01063.x 15634270
12. Schwarz UR Geiger J Walter U Eigenthaler M Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 1999, 82(3):1145-1152 10494779
13. Geiger J Teichmann L Grossmann R Aktas B Steigerwald U Walter U Schinzel R Monitoring of clopidogrel action: Comparison of methods Clin Chem 2005, 51(6):957-965 10.1373/clinchem.2004.047050 15817818
14. Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C Rao AK Aspirin resistance: Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 2005, 3:1309-1311 10.1111/j.1538-7836.2005.01351.x 15892858
15. Wallentin L Varenhorst C James S Erlinge D Braun OO Jakubowski JA Sugidachi A Winters KJ Siegbahn A Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 2008, 29(1):21-30 10.1093/eurheartj/ehm545 18055486
16. Wiviott SD Trenk D Frelinger AL O'Donoghue M Neumann FJ Michelson AD Angiolillo DJ Hod H Montalescot G Miller DL Jakubowski JA Cairns R Murphy SA McCabe CH Antman EM Braunwald E PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 2007, 116(25):2923-2932 10.1161/ CIRCULATIONAHA.107.740324 18056526
17. Brandt JT Payne CD Wiviott SD Weerakkody G Farid NA Small DS Jakubowski JA Naganuma H Winters KJ A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation Am Heart J 2007, 153:66.e9-66.e16 10.1016/j.ahj.2006.10.010
18. Wiviott SD Braunwald E McCabe CH Montalescot G Ruzyllo W Gottlieb S Neumann FJ Ardissino D DeServi S Murphy SA Riesmeyer J Weerakkady G Gibson CM Antman EM TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Eng J Med 2007, 357:2001-2015 10.1056/NEJMoa0706482
19. Steinhubl SR Berger PB Brennan DM Topol EJ CREDO Investigators Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention J Am Coll Cardiol 2006, 47(5):939-943 10.1016/j.jacc.2005.10.047 16516075
20. Bhatt DL Intensifying Platelet Inhibition - Navigating between Scylla and Charybdis New Engl J Med 2007, 357:2078-2081 10.1056/NEJMe0706859 17982183
21. Gachet C Aleil B Testing antiplatelet therapy Eur Heart J Suppl 2008, 10(suppl A):A28-A34 10.1093/eurheartj/sum081